MG0007: An Open-Label Extension Study to Evaluation Rozanolixizumab In Study Participants with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusActive
Effective start/end date1/26/213/8/23

Funding

  • Parexel International LLC: $168,603.00